---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003671"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:55:08.477386+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026

## Summary
- Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.
- Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.
- NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.
- LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.
- Cash runway now expected into second half of 2026 following restructuring and cost reductions.

## SEC filing metadata
- accession: 0001558370-24-003671
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/0001558370-24-003671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/nxtc-20240321x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003671
- JSON: https://secwatch.observer/filing/0001558370-24-003671.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003671.txt

## Key facts
- Earnings Releases
  NextCure, Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000155837024003671/0001558370-24-003671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.